Evidence map›Paper›PMID 40758944›Full record

ArticleBlood2025

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund and 9 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Joshua RiveraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Qi YanDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-5963-9242
Saeed DaneshmandiDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0001-7817-3006
Romain LannesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-6672-1762
Eriko KatsutaDepartment of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.ORCID 0000-0001-5862-2919
JeeEun ChoiDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Prashant SinghDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Ahmed BelalDepartment of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Ronald AlbericoDepartment of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Ian LundDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Megan SchaeferDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Hamza HassanDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0003-1775-2703
Sarah ParkerDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Kenneth C AndersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Nikhil C MunshiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Mehmet SamurDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Philip L McCarthyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-9577-3879
Jens HillengassDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-1778-0010
Hemn MohammadpourDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-0158-7283

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Nikhil C. Munshi · 2011 to 2026
$32.5M
Director Genomics Shared ResourceR50CA283805 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Prashant Kumar Singh · 2024 to 2026
$708k
NCI NIH HHS P01 CA155258NCI NIH HHS R50 CA283805
6 · The paper itself

Abstract

abstractUnderstanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting multiple myeloma (MM). Neutrophils are a new cancer research focus due to their potential to reduce the efficacy of immune-based therapies. This study aimed to deepen understanding of neutrophil function in MM by analyzing freshly isolated myeloid cells from paired focal lesions (FLs) and bone marrow using single-cell RNA sequencing, immunofluorescence imaging, and functional assays. We describe 3 distinct CXCR2+ mature neutrophil subsets: TREM1+CD10+, RETN+LCN2+, and TNFAIP3+CXCL8+, each exhibiting unique phenotypes within the TME. Notably, the TREM1+CD10+ subset was highly prevalent, particularly in FLs, demonstrating potent immunosuppressive effects on T cells. This subset's gene signature was correlated with shorter overall survival (OS) in a large data set of patients with MM, underscoring its clinical significance. Targeted inhibition of neutrophil activity through CXCR2 blockade, alone or combined with standard anti-MM therapies, significantly reduced tumor burden, improving OS in preclinical MM models. These insights into neutrophil-mediated immunosuppression in MM provide valuable knowledge regarding mechanisms driving immune evasion, and reveal new therapeutic approaches to enhance the efficacy of MM treatment.

Indexed as

Immune ToleranceMultiple MyelomaNeutrophilsTumor MicroenvironmentAnimalsFemaleHumansMaleMiceReceptors, Interleukin-8BReceptors, Interleukin-8B

Identifiers

PMID40758944
PMCPMC12824687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.